விரைவுபடுத்து வணிகமயமாக்கல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from விரைவுபடுத்து வணிகமயமாக்கல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In விரைவுபடுத்து வணிகமயமாக்கல் Today - Breaking & Trending Today

Plus, a Global Provider of Self-Driving Truck Technology, to Become Publicly Listed Through Business Combination with Hennessy Capital Investment Corp. V


Share:
Autonomous Trucking Technology Company Plans to Start Mass Production in 2021
Proprietary Full-Stack Level 4 ( L4 ) Software is Behind the Decision-Making Required to Autonomously, Safely and Intelligently Drive the Vehicle
Post-Combination Represents Market Capitalization of $3.3 Billion for Plus
Plus to Add Up to Approximately $500 Million in Gross Proceeds to Accelerate Commercialization and Expand Global Operations
Transaction Supported by $150 Million PIPE, Including Investments From Funds and Accounts Managed by BlackRock and the D. E. Shaw Group, Among Other Institutional Investors
CUPERTINO, Calif. and NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Plus (formerly Plus.ai) (the Company ), a global provider of self-driving truck technology, announced it has entered into a definitive business combination agreement with Hennessy Capital Investment Corp. V (NASDAQ:HCIC) ( HCIC V or Hennessy Capital ), a publicly traded special purpose acquisition ....

United States , Nicholasa Petruska , Cody Slach , Joele Frank , V Goldman Sachs , David Liu , Danielj Hennessy , Owen Han , Wilkinson Brimmer Katcher , Lauren Kwan , Sidley Austin , Barclays Capital Inc , Hennessy Capital Investment Corp , Goldman Sachs , Software Is Behind The Decision , Kirkland Ellis , Exchange Commission , De Shaw Group , Shearman Sterling , Autonomous Trucking Technology Company Plans , Start Mass Production , Full Stack Level , Decision Making Required , Intelligently Drive , Combination Represents Market Capitalization , Gross Proceeds ,

Roche's arthritis drug Actemra scores FDA nod in rare autoimmune disease after partial clinical win


Mar 5, 2021 11:20am
Roche s Actemra has become the first biologic that the FDA approved for patients with systemic sclerosis-associated interstitial lung disease. (Roche/Genentech)
Missed the primary endpoint of a clinical trial? No problem. We’ll pick the study apart and approve your drug based on a post-hoc subgroup analysis.
That’s what the FDA did in granting Roche’s Actemra a go-ahead in patients with interstitial lung disease (ILD) associated with the rare autoimmune disease systemic sclerosis (SSc).
The approval makes Actemra the first biologic drug cleared by the FDA to slow the decline in pulmonary function in patients with SSc-ILD, Roche’s Genentech said Thursday. ....

Roche Actemra , Roche Genentech , National Institute For Health Research , Uncover Rare Disease Insights , Accelerate Commercialization , Improve Patient , Rodnan Skin , Gilead Science , National Institute , Health Research , Autoimmune Diseases , Rare Diseases , Sfda Approvals , ரோச் ஜெநிஂடெக் , தேசிய நிறுவனம் க்கு ஆரோக்கியம் ஆராய்ச்சி , விரைவுபடுத்து வணிகமயமாக்கல் , மேம்படுத்த நோயாளி , கிலியட் அறிவியல் , தேசிய நிறுவனம் , ஆரோக்கியம் ஆராய்ச்சி , ஆட்டோ இம்யூன் நோய்கள் , ரேர் நோய்கள் ,

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi


Mar 5, 2021 11:23am
Novartis Kymriah is ready for new CAR-T competition from Bristol Myers Squibb, an exec said. (Novartis)
With the FDA’s recent approval for Bristol Myers Squibb’s Breyanzi, a new pharma giant is entering the CAR-T lymphoma fray. But with new, impressive real-world data and a global manufacturing expansion under its belt, rival Novartis says it s ready to rumble.
Novartis last year opened CAR-T production sites in Switzerland and France, while a partner opened a facility in Japan. Another partner, Cell Therapies, has since opened the first CAR-T manufacturing site in Australia. Now, the Swiss drugmaker can call on seven CAR-T manufacturing sites on four continents.  ....

Bristol Breyanzi , Novarti Kymriah , Stefan Hendriks , Penn Abramson Cancer Center , Bristol Myers Squibb , Cell Therapies , Uncover Rare Disease Insights , Accelerate Commercialization , Improve Patient , Abramson Cancer Center , Gilead Sciences , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , செல் சிகிச்சைகள் , விரைவுபடுத்து வணிகமயமாக்கல் , மேம்படுத்த நோயாளி , கிலியட் அறிவியல் ,

Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use


Mar 3, 2021 9:55am
Novartis presented positive study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum from nurses and patients using its Kesimpta auto-injector pen for MS. (Novartis)
Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses.
Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over rival administration methods.
The kudos from a small, 130-participant study come as Novartis bids to make Kesimpta a first-treatment option. Kesimpta’s chief rival Roche’s Ocrevus, which also works by targeting CD20-expressing B-cells is an infusion treatment. ....

Roche Ocrevus , Amy Perrin Ross , Estelle Vester Blokland , Americas Committee For Treatment , Research In Multiple Sclerosis Forum , Americas Committee , Multiple Sclerosis Forum , Uncover Rare Disease Insights , Accelerate Commercialization , Improve Patient , Perrin Ross , Multiple Sclerosis , Dtc Advertising , ஆமி பெர்ரின் ரோஸ் , அமெரிக்காக்கள் குழு க்கு சிகிச்சை , ஆராய்ச்சி இல் பல ஸ்க்லரோசிஸ் மன்றம் , அமெரிக்காக்கள் குழு , பல ஸ்க்லரோசிஸ் மன்றம் , விரைவுபடுத்து வணிகமயமாக்கல் , மேம்படுத்த நோயாளி , பெர்ரின் ரோஸ் , பல ஸ்க்லரோசிஸ் ,